Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial

• DOI: 10.1359/jbmr.040512
• Publication Date: 2006-04-27T00:44:52Z
• Authors: Douglas C Bauer; Dennis M Black; Patrick Garnero; Marc Hochberg; Susan Ott; John Orloff; Desmond E Thompson; Susan K Ewing; Pierre D Delmas
• Keywords: Bone remodeling; Alendronic acid; Hip Fracture; N-terminal telopeptide

Abstract We used data from the Fracture Intervention Trial to assess relationship change in bone turnover after 1 year of alendronate or placebo treatment and subsequent hip, non-spine, spine fracture risk among 6186 postmenopausal women. In group (n = 3105), greater reductions one more biochemical marker were associated with a lower fracture. Introduction: There are few on between short-term markers non-spine bisphosphonate-treated women, clinical use such measurements is unknown. Materials Methods: measured (bone-specific alkaline phosphatase [bone ALP], intact N-terminal propeptide type I collagen, C-terminal crosslinked telopeptide collagen) BMD hip at baseline placebo. During mean follow-up 3.6 years, 72 786 336 vertebral fractures documented. Results Conclusions: Each SD reduction 1-year ALP was fewer (odds ratio 0.74; CI: 0.63, 0.87), (relative hazard [RH] 0.89; 0.78, 1.00; p < 0.050), (RH 0.61; 0.46, 0.78). Alendronate-treated women least 30% had 0.72; 0.55, 0.92) 0.26; 0.08, 0.83) relative those <30%. conclude that therapy fractures, effect as strong observed BMD.